Subject Enrollment. Principal Investigator and Institution (through the actions of the Principal Investigator) have agreed to enroll qualified Study participants during the Pfizer-specified enrollment period, unless CRO, upon Pfizer’s prior instructions, modifies the enrollment period by written notice. A qualified participant is one who meets all Protocol criteria for inclusion in the Study (“Study Subject”). 4.
Subject Enrollment. The Principal Investigator shall enroll subjects into the Study in accordance with the applicable SOW and the applicable Protocol (each a “Subject”). The Principal Investigator shall use all reasonable efforts to complete enrollment prior to any Subject Enrollment Closing Date set forth in writing to the Principal Investigator by SPONSOR. The Study period and the number of Subjects the Institution may enroll in the Study may be extended or shortened at SPONSOR’s sole discretion. The Institution acknowledges and agrees that if a Study is part of a study taking place at multiple sites (a “Multi-Center Study”), that when the enrollment goal for such Multi-Center Study as a whole is reached, enrollment will be closed at all sites, including the Institution, regardless of whether the Institution or any other site has reached its individual enrollment goal.
Subject Enrollment. Institution shall ensure that Principal Investigator shall only enroll Subjects that meet the applicable Protocol requirements. Institution shall ensure that Principal Investigator shall exercise independent medical judgment as to the compatibility of each Subject with the Protocol requirements.
Subject Enrollment. Principal Investigator and Institution (through the actions of the Principal Investigator) have agreed to enroll qualified Study participants during the Pfizer-specified enrollment period, unless CRO, upon Pfizer’s prior 4. Zařazení subjektů. Hlavní zkoušející a Instituce se dohodli, že v průběhu doby stanovené společností Pfizer zařadí (prostřednictvím Hlavního zkoušejícího) do Studie způsobilé účastníky Studie, ledaže CRO na základě předchozích instructions, modifies the enrollment period by written notice. A qualified participant is one who meets all Protocol criteria for inclusion in the Study (“Study Subject”). pokynů společnosti Pfizer nezmění období zařazování písemným oznámením. Způsobilý účastník je osoba, která splňuje všechna kritéria Protokolu pro zařazení do Studie (dále jen „Subjekt studie“).
Subject Enrollment. The Institution and the Principal Investigator have agreed to endeavor to enroll in the Study an estimated quantity of but not more than qualified Study participants by , unless the Sponsor, upon the Sponsor’s prior instructions, modifies this enrollment period by written notice. A qualified participant is one who meets all Protocol criteria for inclusion in the Study (hereinafter, a “Study Subject”). [Revise if only a minimum or only a maximum number will be specified but not both]
Subject Enrollment. The Institution and the Principal Investigator have agreed to enroll qualified Study participants during the Sponsor-specified enrollment period, unless the Sponsor modifies the enrollment period by written notice. A qualified participant is one who meets all Protocol criteria for inclusion in the Study ("Study Subject").
Subject Enrollment. Principal Investigator has agreed to enroll qualified Study subjects during the CRO-specified enrollment period, unless CRO modifies the enrollment period by written notice. A qualified subject is one who meets all Protocol criteria for inclusion in the Study (“Study Subject”).
Subject Enrollment. Principal Investigator will enroll in the Study a minimum of but no more than qualified subjects by Mmm dd, yyyy, unless Sponsor extends this enrollment period by written notification. A qualified subject is one who meets all Protocol criteria for inclusion in the Study.
Subject Enrollment. Provider shall ensure that Principal Investigator shall only enroll Subjects that meet the applicable Protocol requirements. Provider shall ensure that Principal Investigator shall exercise independent medical judgment as to the compatibility of each Subject with the Protocol requirements. The Provider agrees to use reasonable efforts to enroll subjects.
Subject Enrollment. For purposes of this Agreement, all individuals enrolled in the Clinical Trial shall be referred to as "Trial Subjects." INSTITUTION and Principal Investigator will use reasonable efforts to enroll the requisite number of Trial Subjects for the Clinical Trial in accordance with the patient eligibility criteria specified in the Protocol. The Principal Investigator shall at all times exercise independent medical judgment as to the suitability of each prospective individual for enrollment as a Trial Subject. The INSTITUTION acknowledges and agrees that the Clinical Trial may be conducted concurrently by SPONSOR at more than one (1) trial center under the same Protocol with concurrent patient enrollment. SPONSOR shall have the right to terminate INSTITUTION's recruitment and enrollment of Trial Subjects at any time that SPONSOR determines that sufficient enrollment has been achieved in any combination of trial centers performing the Clinical Trial. SPONSOR, in its sole discretion, may extend the enrollment period upon written notice to INSTITUTION.
